SIGA is slated to receive FDA approval for the world’s first antiviral drug to treat smallpox – a milestone not reached in isolation, but in collaboration with several CROs, government agencies, and others.
The preclinical contract research organization (CRO) Admescope has acquired MetaSafe in a deal which will bolster its drug metabolism services for clinical phase projects.
Celltrion has launched Bio CDMO, its new contract development and manufacturing business and part of the company's "open innovation strategy" to expand its drug pipeline portfolio.
Syngene International has inked a non-exclusive partnering agreement with the emerging immuno-oncology company Zumutor Biologics after collaborating for more than a year.
The Northern Ireland development agency Invest NI has awarded Fusion Antibodies a grant worth up to £213,000 ($283,231), which will help the CRO double its capacity and employee count.
Lonza has added to its hepatocytes portfolio to provide researchers with the foundation to create “more physiologically relevant” in vitro models for liver disease research.
Bayer AG and Elsevier studied more than 1.6m adverse events to show how big data can be used to reduce animal testing and design trials "altered to potential risks," says researcher.
AstraZeneca is embedding Emulate’s Organ-on-Chips technology – and scientists – within its laboratories to further develop the technology as part of a strategic agreement, “with the overall goal to accelerate drug discovery,” says exec.
XenoGesis and BioAscent have teamed up to fill "a gap in the market" for integrated drug discovery services aimed at biotech, mid-sized pharma, and academic drug developers, says CEO.
PolarityTE has acquired a preclinical biomedical research facility which will serve as a CRO to accelerate research and development and “help drive the field of biotechnology,” says CEO.
Evotec has entered into a strategic collaboration to accelerate Carna Biosciences’s program CB-1763, which is being developed for the treatment of blood cancer.
Sanofi has awarded Meditope Biosciences a BioLabs’ “Golden Ticket” to support the development of its bioconjugation platform and create new antibody-based therapeutic constructs.
Scientists at the University of Leeds may have found a new way to reduce the number of animals used in research while also gaining improved insight into treating cancer and other diseases.
A new method for determining the crystal structures of organic salts – which make up 40% of all APIs – could “greatly speed up” the drug development process, say researchers.
Catalent plans to invest $5m to create a new drug development center of excellence focusing on preclinical to clinical phase IIb formulation, analytical, and manufacturing solutions.
WuXi AppTec is converting its Plainsboro, NJ lab into a fully GLP-regulated bioanalytics facility after opening a new site in Cranbury which doubles the company’s total operation space to more than 115,000 square feet.
Poor animal study design and reporting raise concerns about whether current processes are the best way to conduct effective and efficient drug development.
Charles River Laboratories and PathoQuest have expanded their strategic partnership to help move vaccine, biologic, and gene-therapy candidates through the drug discovery and development pipeline.
ImmunoPrecise Antibodies has acquired ModiQuest Research BV to create a “single source provider of services across the full antibody discovery value chain,” says CRO.
The synthetic DNA provider Twist Bioscience Corporation has completed a private placement of $50m to advance its proprietary, silicon-based DNA Synthesis Platform.
PPD has expanded its Middleton, WI-based GMP analytical laboratory, increasing its large molecule development capacity with space for more than 100 new employees.
Syngene International has signed a multiyear agreement with GSK through which the companies will focus on accelerating the discovery of new drug candidates using the CRO’s discovery services platforms.
Envigo is increasing its surgical footprint ten-fold to create a West Coast Center of Excellence for surgery and supply myocardial infarction research models regionally.
Covance has formed a global immunology and immunotoxicology (I&I) unit, which will be dedicated to the “innovative and complex” approaches required by biologics, says CRO.
The non-clinical contract research organization (CRO) Citoxlab Group has acquired Solvo Biotechnology, a CRO specializing in drug transporters studies and the assessment of drug-drug interactions (DDI).
Trans-Hit Bio and Q&T Research have entered into an exclusive strategic partnership, which will provide biopharma customers with access to human biospecimens, for which there is “a great demand,” says exec.
A new method to predict the physical stability of drug candidates is attracting interest from pharmaceutical companies who could use the technology to de-risk early development.
Charles River has made several expansions across the globe, including a new, 73,000 square-foot facility in Wayne, PA, which doubles its laboratory footprint in the state.
Standardization in preclinical animal studies may be a cause of poor reproducibility – making translation to humans in clinical trials difficult, if unlikely, say researchers.
Charles River has launched a new online tool to help researchers design in vitro and in vivo oncology research studies – to put the power of data in the hands of scientists, says exec.
Scientist.com is working to implement an improved contractual landscape ahead of GDPR implementation in May, in order to ensure global compliance among sponsors and CROs.
Certara has acquired BaseCase Management GmbH, a data visualization company that helps sponsors communicate health economic evidence and product differentiation information.
Charles River has been granted commercial access to AstraZeneca’s high-throughput screening (HTS) and compound management infrastructure, an investment that will help the company "deliver optimal benefit" to its customers, says executive.
Biomedical and pharmaceutical stakeholders have heralded the news that Chinese researchers have successfully cloned a monkey and its potential to unlock further our understanding of complex diseases.
Metrion Biosciences has acquired a portfolio of more than 2,000 small molecule potassium channel inhibitors from Japan Tobacco Inc. (JT), with potential application in a variety of clinical indications.
XtalPi is advancing artificial intelligence models and prediction-driven research capabilities to improve drug design and small molecule development services.
